Why Conventional Psoriasis Treatments Fail—and the Path to True Healing

What’s the Deal with My Psoriasis Treatment? Why Can’t I Come Out of Psoriasis?

Psoriasis is a chronic autoimmune skin condition that manifests in several forms, each with varying severity and requiring individualized treatment (Langley, Krueger, & Griffiths, 2005; Parisi et al., 2013). Its unpredictable nature, coupled with the inadequacies of conventional treatments, often leaves patients stuck in cycles of flare-ups and temporary relief (Feldman et al., 2008). This is not due to a lack of effort but rather a failure to address the root cause of the disease (Upadhyay, 2010).

At EliteAyurveda, we meet many patients frustrated with their conventional treatments. By focusing on personalized Ayurvedic solutions, we help them break free from this cycle and move toward sustained remission (Singh, 2010).

Why Conventional Psoriasis Treatments Fail

Why Allopathic Treatments for Psoriasis Often Fail

There are several reasons why conventional treatments lose their efficacy or fail entirely (Koo & Lebwohl, 1999):

1. Drug Tolerance (Tachyphylaxis)

Conventional treatments such as corticosteroids and non-steroidal topical therapies often lose effectiveness with prolonged use. This phenomenon, known as tachyphylaxis, occurs because the body develops a resistance to the treatment (Koo & Lebwohl, 1999).

• Example: A patient using topical steroids may find that after a few months, their blisters and plaques no longer respond as they once did. This leads to frustration and the need for stronger medications, increasing the risk of side effects (Feldman et al., 2008).

2. Toxicity Accumulation

Systemic medications like methotrexate or cyclosporine, while effective initially, often result in toxic buildup in vital organs over time (Menter et al., 2019). Similarly, prolonged phototherapy is linked to an increased risk of skin cancer (Menter et al., 2019).

• Real Case: A 40-year-old female patient came to us after developing liver toxicity from methotrexate use over 8 years. Though her psoriasis was temporarily managed, the severe side effects forced her to discontinue the treatment.

3. Development of Anti-Drug Antibodies (ADAs)

When using biologic therapies, the body may develop anti-drug antibodies, reducing the efficacy of these treatments. This leads to what is known as biologic fatigue, where medications that once provided relief no longer work (Dommasch et al., 2018).

• Observation: In our clinic, we frequently see patients who initially experienced remarkable improvement with biologics but later faced diminishing results and relapses within 6 months to a year (Dommasch et al., 2018).

4. Misdiagnosis or Incomplete Diagnosis

Psoriasis can sometimes be misdiagnosed as eczema or contact dermatitis. Without a correct diagnosis, patients may be subjected to inappropriate treatments that worsen their condition (Nair, 2018).

• Example: A male patient, initially treated for fungal dermatitis, visited us after a year of worsening symptoms, which were later correctly identified as guttate psoriasis.

5. Psychological and Financial Barriers

The high costs of biologic drugs make them inaccessible to many, while the psychological toll of managing a chronic illness can lead to missed doses or inconsistent treatment (National Psoriasis Foundation, n.d.). Stress, a known trigger for psoriasis flare-ups, further exacerbates the condition (Feldman et al., 2008).

The Difference Between Control and Reversal in Psoriasis Treatment

Control-Centric Approach

In conventional medicine, psoriasis treatment is often focused on managing symptoms—reducing redness, scaling, and inflammation through medications or phototherapy (Menter et al., 2019). While these measures provide temporary relief, they fail to address the deeper imbalances causing the condition (Upadhyay, 2010).

• Outcome: Patients may experience periods of remission but are often reliant on lifelong medications with mounting side effects (Koo & Lebwohl, 1999).

Reversal-Centric Approach

At EliteAyurveda, we focus on true reversal, which involves:

1. Identifying and addressing the root causes of psoriasis (Singh, 2010).
2. Balancing the body’s systems, including digestion, immunity, and detoxification pathways (Upadhyay, 2010).
3. Reducing reliance on external medications by empowering the body to heal itself (Nair, 2018).

Common Reasons Patients Struggle with Psoriasis Reversal

Here are some of the challenges patients face before switching to Ayurveda (Nair, 2018):

1. Incomplete Remission: Conventional medications suppress symptoms but do not prevent flare-ups (Koo & Lebwohl, 1999).
2. Overlapping Conditions: Comorbidities like diabetes, heart disease, or depression complicate treatment plans (Parisi et al., 2013).
3. Impatience with Long-Term Plans: Biologic therapies often take months to show results, and even then, they may not deliver complete relief (Dommasch et al., 2018).

Our Approach at EliteAyurveda

Personalized Root-Cause Treatment

Unlike generic treatments, we develop individualized plans based on each patient’s unique constitution (Prakriti) and specific imbalances (Singh, 2010).

Key Elements of Our Treatment

1. Detoxification (Shodhana):

• Gentle internal detox protocols to cleanse the liver and blood (Nair, 2018).

1. Personalized Herbal Medications:

• Tailored herbal formulations to pacify aggravated Pitta and strengthen the immune system (Upadhyay, 2010).

1. Dietary Guidance:

• Cooling foods like coconut water and cucumber to calm inflammation (Singh, 2010).
• Avoidance of Pitta-aggravating foods such as spicy and processed items (Nair, 2018).

1. Lifestyle Adjustments:

• Stress management through yoga and meditation (Singh, 2010).
• Daily routines to restore circadian rhythms and stabilize immunity (Upadhyay, 2010).

Case Study: Breaking Free from Psoriasis

Patient Profile:

• Name: Mr. Suresh (Name Changed)
• Age: 35
• Symptoms: Scaly patches covering 40% of his body, severe itching, and joint pain.
• Previous Treatment: Biologics for 5 years with diminishing returns and new side effects, including chronic fatigue (Dommasch et al., 2018).

Ayurvedic Treatment Plan:

1. Detoxification: Weekly specialized therapies to cleanse the liver and eliminate toxins (Upadhyay, 2010).
2. Herbal Support: Personalized medications to balance Pitta and support skin healing (Singh, 2010).
3. Dietary Adjustments: Pitta-pacifying diet with cooling foods and hydration-focused meals (Nair, 2018).
4. Stress Reduction: Pranayama and guided meditation for emotional balance (Singh, 2010).

Outcome:

• Within 2 months: Reduced scaling and itching.
• Within 6 months: Clear skin and improved joint mobility.
• Sustained remission for 3 years with no dependence on biologics.

From the Doctor’s Desk: Why Choose Ayurveda?

• Sustainable Healing: True psoriasis reversal is possible by addressing its root causes (Upadhyay, 2010).
• Fewer Side Effects: Herbal medications offer relief without the toxicity of systemic drugs (Nair, 2018).
• Holistic Care: We focus on the whole body, not just the skin (Singh, 2010).

Takeaway

Psoriasis is a complex condition requiring more than symptomatic control. While conventional treatments often focus on managing flare-ups, they fail to address the underlying causes, leaving patients in a cycle of dependency and relapse (Koo & Lebwohl, 1999). Ayurveda provides a path to true healing by addressing the root causes and restoring balance to the body (Upadhyay, 2010).

At EliteAyurveda, we specialize in empowering patients with natural, personalized treatments for sustained relief and improved quality of life.

Take the first step toward psoriasis reversal today.📞 Contact us at +91 8884722246🌐 Visit our website: www.eliteayurveda.com

Related-

Know More About Ayurveda Treatment For Psoriasis

GET IN TOUCH

Schedule a Visit

Contact us

References

1.World Health O. Global Report on Psoriasis. World Health Organization; Geneva, Switzerland: 2016. [Google Scholar]

2.Griffiths C.E.M., Armstrong A.W., Gudjonsson J.E., Barker J. Psoriasis. Lancet. 2021;397:1301–1315. doi: 10.1016/S0140-6736(20)32549-6. [DOI] [PubMed] [Google Scholar]

3.Armstrong A.W., Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323:1945–1960. doi: 10.1001/jama.2020.4006. [DOI] [PubMed] [Google Scholar]

4.Kaushik S.B., Lebwohl M.G. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J. Am. Acad. Dermatol. 2019;80:27–40. doi: 10.1016/j.jaad.2018.06.057. [DOI] [PubMed] [Google Scholar]

5.Reid C., Griffiths C.E.M. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm.-Venereol. 2020;100:adv00032. doi: 10.2340/00015555-3386. [DOI] [PMC free article] [PubMed] [Google Scholar]

6.Singh A., Easwari T.S. Recent Advances in Psoriasis Therapy: Trends and Future Prospects. Curr. Drug Targets. 2021;22:1760–1771. doi: 10.2174/1389450122666210118103455. [DOI] [PubMed] [Google Scholar]

7.Gyldenløve M., Alinaghi F., Zachariae C., Skov L., Egeberg A. Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review. Am. J. Clin. Dermatol. 2022;23:605–613. doi: 10.1007/s40257-022-00703-1. [DOI] [PubMed] [Google Scholar]

8.Hsieh T.S., Tsai T.F. Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review. Dermatol. Ther. 2023;13:891–909. doi: 10.1007/s13555-023-00903-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

9.Pourani M.R., Abdollahimajd F., Zargari O., Shahidi Dadras M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J. Dermatol. Treat. 2022;33:1967–1974. doi: 10.1080/09546634.2021.1966357. [DOI] [PubMed] [Google Scholar]

10.Lwin S.M., Snowden J.A., Griffiths C.E.M. The promise and challenges of cell therapy for psoriasis. Br. J. Dermatol. 2021;185:887–898. doi: 10.1111/bjd.20517. [DOI] [PubMed] [Google Scholar]

11.Salgado-Boquete L., Carrascosa J.M., Llamas-Velasco M., Ruiz-Villaverde R., de la Cueva P., Belinchón I. A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis? Life. 2021;11:627. doi: 10.3390/life11070627. [DOI] [PMC free article] [PubMed] [Google Scholar]

12.Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C.E., Nast A., Franke J., Antoniou C., Arenberger P., Balieva F., et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res. 2011;303:1–10. doi: 10.1007/s00403-010-1080-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

13.Oranje A.P., Marcoux D., Svensson A., Prendiville J., Krafchik B., Toole J., Rosenthal D., de Waard-van der Spek F.B., Molin L., Axelsen M. Topical calcipotriol in childhood psoriasis. J. Am. Acad. Dermatol. 1997;36:203–208. doi: 10.1016/S0190-9622(97)70281-0. [DOI] [PubMed] [Google Scholar]

14.Maul J.T., Anzengruber F., Conrad C., Cozzio A., Häusermann P., Jalili A., Kolios A.G.A., Laffitte E., Lapointe A.K., Mainetti C., et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology. 2021;237:166–178. doi: 10.1159/000512930. [DOI] [PubMed] [Google Scholar]

15.Elmets C.A., Korman N.J., Prater E.F., Wong E.B., Rupani R.N., Kivelevitch D., Armstrong A.W., Connor C., Cordoro K.M., Davis D.M.R., et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J. Am. Acad. Dermatol. 2021;84:432–470. doi: 10.1016/j.jaad.2020.07.087. [DOI] [PubMed] [Google Scholar]

16.Blauvelt A., Leonardi C.L., Gooderham M., Papp K.A., Philipp S., Wu J.J., Igarashi A., Flack M., Geng Z., Wu T., et al. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156:649–658. doi: 10.1001/jamadermatol.2020.0723. [DOI] [PMC free article] [PubMed] [Google Scholar]

17.Gold L.S., Lebwohl M.G., Sugarman J.L., Pariser D.M., Lin T., Martin G., Pillai R., Israel R., Ramakrishna T. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J. Am. Acad. Dermatol. 2018;79:287–293. doi: 10.1016/j.jaad.2018.03.040. [DOI] [PubMed] [Google Scholar]

18.Lis-Święty A., Frątczak A. Proactive therapy: New perspectives for long-term topical treatment of psoriasis. Dermatol. Ther. 2022;35:e15364. doi: 10.1111/dth.15364. [DOI] [PubMed] [Google Scholar]

19.Soleymani T., Hung T., Soung J. The role of vitamin D in psoriasis: A review. Int. J. Dermatol. 2015;54:383–392. doi: 10.1111/ijd.12790. [DOI] [PubMed] [Google Scholar]

20.Amiri D., Schwarz C.W., Gether L., Skov L. Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review. Acta Derm.-Venereol. 2023;103:adv00890. doi: 10.2340/actadv.v103.6525. [DOI] [PMC free article] [PubMed] [Google Scholar]

21.Fritz K., Salavastru C. The 308 nm Excimer laser for the treatment of psoriasis and inflammatory skin diseases. Der Hautarzt Z. Dermatol. Venerol. Verwandte Geb. 2018;69:35–43. doi: 10.1007/s00105-017-4105-2. [DOI] [PubMed] [Google Scholar]

22.Menter A., Strober B.E., Kaplan D.H., Kivelevitch D., Prater E.F., Stoff B., Armstrong A.W., Connor C., Cordoro K.M., Davis D.M.R., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 2019;80:1029–1072. doi: 10.1016/j.jaad.2018.11.057. [DOI] [PubMed] [Google Scholar]

23.Menter A., Gelfand J.M., Connor C., Armstrong A.W., Cordoro K.M., Davis D.M.R., Elewski B.E., Gordon K.B., Gottlieb A.B., Kaplan D.H., et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J. Am. Acad. Dermatol. 2020;82:1445–1486. doi: 10.1016/j.jaad.2020.02.044. [DOI] [PubMed] [Google Scholar]

24.Elmets C.A., Lim H.W., Stoff B., Connor C., Cordoro K.M., Lebwohl M., Armstrong A.W., Davis D.M.R., Elewski B.E., Gelfand J.M., et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J. Am. Acad. Dermatol. 2019;81:775–804. doi: 10.1016/j.jaad.2019.04.042. [DOI] [PubMed] [Google Scholar]

25.Lambert J.L.W., Segaert S., Ghislain P.D., Hillary T., Nikkels A., Willaert F., Lambert J., Speeckaert R. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1) J. Eur. Acad. Dermatol. Venereol. JEADV. 2020;34:1654–1665. doi: 10.1111/jdv.16684. [DOI] [PMC free article] [PubMed] [Google Scholar]

26.Armstrong A.W., Puig L., Joshi A., Skup M., Williams D., Li J., Betts K.A., Augustin M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020;156:258–269. doi: 10.1001/jamadermatol.2019.4029. [DOI] [PMC free article] [PubMed] [Google Scholar]

27.Kimball A.B., Rothman K.J., Kricorian G., Pariser D., Yamauchi P.S., Menter A., Teller C.F., Aras G., Accortt N.A., Hooper M., et al. OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J. Am. Acad. Dermatol. 2015;72:115–122. doi: 10.1016/j.jaad.2014.08.050. [DOI] [PMC free article] [PubMed] [Google Scholar]

28.Menter A., Thaçi D., Wu J.J., Abramovits W., Kerdel F., Arikan D., Guo D., Ganguli A., Bereswill M., Camez A., et al. Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatol. Ther. 2017;7:365–381. doi: 10.1007/s13555-017-0198-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

29.Kalb R.E., Fiorentino D.F., Lebwohl M.G., Toole J., Poulin Y., Cohen A.D., Goyal K., Fakharzadeh S., Calabro S., Chevrier M., et al. Risk of Serious Infection with Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) JAMA Dermatol. 2015;151:961–969. doi: 10.1001/jamadermatol.2015.0718. [DOI] [PubMed] [Google Scholar]